Cannabis-related disorders, hospitalization, and cardiovascular outcomes in patients with heart failure: A real-world propensity-matched cohort study
Clinical Research in Cardiology · 18.11.2026
DOI: 10.1007/s00392-026-03056-5 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Research in Cardiology, online erschienen am 18.11.2026. Verfasst von Niti Dalal und 7 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
The clinical implications of cannabis exposure in patients with heart failure remain uncertain. We evaluated the associations between a documented cannabis-related disorder (CRD) and hospitalization and cardiovascular outcomes in a large real-world heart failure cohort.
Methods
We performed a retrospective cohort study using the TriNetX US Collaborative Network. Adult patients with heart failure (ICD-10-CM I50) were identified and stratified by the presence or absence of cannabis-related disorder (ICD-10-CM F12) recorded within 1 year on or before the first heart failure diagnosis, which served as the index date. The primary outcome was all-cause hospitalization at 1 year. Secondary outcomes included stroke, myocardial infarction, end-stage renal disease, atrial fibrillation/flutter, and all-cause mortality. Follow-up began 1 day after the index date; patients with a prior history of a given outcome were excluded from that analysis. One-to-one propensity score matching was performed using 26 baseline covariates.
Results
After matching, 30,624 patients were included in each cohort. At 1 year, a documented CRD was associated with a higher risk of hospitalization (57.5% vs. 45.1%; HR, 1.468; 95% CI, 1.436–1.501; p < 0.001). A documented CRD was also associated with significantly higher all-cause mortality (10.4% vs 9.3%; HR, 1.147; 95% CI, 1.090–1.207; p < 0.001), stroke (2.9% vs 2.3%; HR, 1.263; 95% CI, 1.138–1.401; p < 0.001), and myocardial infarction (6.0% vs 4.4%; HR, 1.415; 95% CI, 1.307–1.531; p < 0.001). Atrial fibrillation/flutter and end-stage renal disease did not differ. The hospitalization association persisted after excluding the first 30 days of follow-up (HR 1.252; 95% CI 1.226–1.280; p < 0.001), was similar in women and men, and remained in multivariable Cox models (adjusted HR 1.521; 95% CI 1.503–1.539; p < 0.001).
Conclusions
In this real-world propensity score–matched cohort of patients with heart failure, a documented cannabis-related disorder was associated with higher risks of hospitalization and selected adverse cardiovascular outcomes. Prospective studies with precise cannabis exposure characterization are needed to confirm these associations.
Zitieren
APA
Dalal, N., Sanadi, M., Karim, H. S., Bengoa, D. S., Desai, S., Munagala, M., Azocar, R. J., & Divya, A. (2026). Cannabis-related disorders, hospitalization, and cardiovascular outcomes in patients with heart failure: A real-world propensity-matched cohort study. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03056-5
Vancouver
Dalal N, Sanadi M, Karim HS, Bengoa DS, Desai S, Munagala M, et al. Cannabis-related disorders, hospitalization, and cardiovascular outcomes in patients with heart failure: A real-world propensity-matched cohort study. Clinical Research in Cardiology. 2026. doi:10.1007/s00392-026-03056-5
BibTeX
@article{Dalal2026,
author = {Dalal, Niti and Sanadi, Mark and Karim, Heeran S. and Bengoa, Dani S. and Desai, Sapna and Munagala, Mrudula and Azocar, Ruben J. and Divya, Aabha},
title = {Cannabis-related disorders, hospitalization, and cardiovascular outcomes in patients with heart failure: A real-world propensity-matched cohort study},
journal = {Clinical Research in Cardiology},
year = {2026},
doi = {10.1007/s00392-026-03056-5}
}
EUVIMED